FCER1G and neoplasm: showed that injection of rituximab to FcRγ-deficient mice was ineffective at a high load of tumor cells and that, in contrast to a challenge with a low number of tumor cells, effective elimination demands the cooperation of complement and ADCC and the presence of functional complement receptor 3 (CR3) on blood phagocytes (34).